Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from InflaRx ( (IFRX) ).
On April 9, 2026, InflaRx reported new in vitro mechanistic data showing that its lead candidate izicopan does not exhibit time-dependent inhibition of CYP3A4, a key enzyme involved in metabolizing many drugs and a common source of drug–drug interactions and liver toxicity. Using a detailed Ki-based time-dependent inhibition study with midazolam and testosterone as probe substrates, the company confirmed no CYP3A4 inhibition up to high concentrations, reinforcing izicopan’s favorable pharmacological profile and its potential best-in-class positioning among oral C5a receptor inhibitors.
The findings build on earlier clinical and preclinical results indicating that izicopan is well tolerated, shows strong C5a blockade, and delivers biologic-like efficacy signals in inflammatory conditions such as hidradenitis suppurativa and chronic spontaneous urticaria. By minimizing the risk of clinically relevant drug–drug interactions, especially with commonly co-administered therapies like corticosteroids, the new data support izicopan’s suitability for chronic use and could strengthen InflaRx’s competitive edge in the growing market for complement-targeted anti-inflammatory drugs.
The most recent analyst rating on (IFRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, sizable ongoing losses, and persistent cash burn). Technicals are roughly neutral with limited momentum, while valuation metrics offer little support due to losses and no indicated dividend yield.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V. is a Germany-based biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement system, particularly the inflammatory mediator C5a and its receptor C5aR. Its lead oral small-molecule candidate izicopan and intravenous antibody vilobelimab are being developed for multiple inflammatory indications, including hidradenitis suppurativa and other complement-mediated diseases.
Average Trading Volume: 419,521
Technical Sentiment Signal: Sell
Current Market Cap: $68.68M
For an in-depth examination of IFRX stock, go to TipRanks’ Overview page.